Sign up USA
Proactive Investors - Run By Investors For Investors

Spine Injury Solutions boosted by new certificates

Medtech group Spine Injury Solutions (OTC:SPIN) added 2.38% to US$0.43 as it got key certifications for its Quad Video HALO System.
Spine Injury Solutions boosted by new certificates
The firm provides services for patients who have sustained spine injuries resulting from traumatic accidents

Medtech group Spine Injury Solutions  (OTC:SPIN) added 2.38% to US$0.43 as it got key certifications for its Quad Video HALO System.

The device is a medical real-time video and documentation accessory and it means it has now completed requirements for sales and marketing of medical applications under both US and EU standards.

Dr William Donovan, chief of Spine Injury Solutions, said: "The QVH has undergone rigorous internal testing and has been used to great success in conjunction with SPIN's medical affiliates in a diagnostic program for treating more than a thousand spine injury cases.

"The QVH not only provides protection for the medical provider, through secure video transparency and real-time documentation of the procedures, but also gives great comfort to the patient knowing his or her medical provider will 'do his best' in performing the procedure."

He added: "Two years ago we realized the potential of the QVH. And, that with modifications, it could be expanded dramatically outside our own needs, not only for use with the tens of thousands of fluoroscopes (both fixed and portable) currently in service, but also in operating rooms world-wide."

The firm says it's now been in discussions with various groups about sales, leasing and marketing of the QVH both in the USA and Europe with focus on teaching hospitals, pain management groups, factoring companies, who deal with personal injury A/R cases, ER/ urgent care centers and hospitals. 


Register here to be notified of future SPIN Company articles

Related Articles

April 28 2016
Last year's acquisition of Kinesis Pharma meant that it could now offer a one-stop shop for its pharmaceuticals clients and expand its client base.
April 12 2016
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
March 31 2016
Amryt Pharmaceuticals will join the London market in a deal that values it at £29.6mln. A share placing, meanwhile, will bring in £10mln to be used to develop the company’s lead treatment for a rare skin disorder.
Copyright ©, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC